Genital Diseases, Female  >>  varlilumab (CDX 1127)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
varlilumab (CDX 1127) / Celldex
NCT02270372: Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

Checkmark For advanced cancer at ASCO 2014
May 2014 - Jun 2014: For advanced cancer at ASCO 2014
Completed
1b
22
US
ONT-10, Varlilumab combination
Cascadian Therapeutics Inc., Celldex Therapeutics
Advanced Breast Carcinoma, Advanced Ovarian Carcinoma
06/16
06/16
NCT01460134: A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Checkmark POC data in solid tumors and hematologic cancers
Apr 2016 - Apr 2016: POC data in solid tumors and hematologic cancers
Checkmark Varlilumab upate
Feb 2015 - Feb 2015: Varlilumab upate
Completed
1
90
US
CDX-1127
Celldex Therapeutics
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Any T-cell Malignancy, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma, Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Burkett's Lymphoma, Primary Lymphoma of the Central Nervous System
12/15
10/17

Download Options